Daniel Levine
Dan@orpheden.com
Dan@orpheden.com
Orpheden has made exciting progress in the previous months. We worked hard to define and source vendors for our near-term operations, established strong relationships with potential angels and strategic investors, and worked with patient advocacy groups to truly understand the need for our dendritic cell therapy. Not to mention our new online presence at www.OrphedenTherapeutics.com and on Twitter @Orpheden
Apparently we are doing something right as we have received repeated recognition for the quality of our budding business: Our license application for Granulysin-Dendritic Cells was accepted by the NIH and posted to the federal register; We were selected as a “featured company” at Techweek Chicago’s WellTECH Summit, an event followed up with national media coverage; Orpheden’s business plan was selected as a “finalist” in the iBIO PROPEL business plan competition, giving us a chance to pitch in front of over 200 investors for the grand prize in August; We pitched during the Northwestern tech transfer office’s annual meeting to their board of directors; And we were nominated for the 13th annual Chicago Innovations Awards, a prestigious entrepreneurship award given in September;
All in all, we are excited to guide Orpheden as it continues to gain momentum towards a flourishing pharmaceutical company.
Apparently we are doing something right as we have received repeated recognition for the quality of our budding business: Our license application for Granulysin-Dendritic Cells was accepted by the NIH and posted to the federal register; We were selected as a “featured company” at Techweek Chicago’s WellTECH Summit, an event followed up with national media coverage; Orpheden’s business plan was selected as a “finalist” in the iBIO PROPEL business plan competition, giving us a chance to pitch in front of over 200 investors for the grand prize in August; We pitched during the Northwestern tech transfer office’s annual meeting to their board of directors; And we were nominated for the 13th annual Chicago Innovations Awards, a prestigious entrepreneurship award given in September;
All in all, we are excited to guide Orpheden as it continues to gain momentum towards a flourishing pharmaceutical company.
RSS Feed